Fulcrum Therapeutics’ (FULC) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report released on Thursday,Benzinga reports. The brokerage currently has a $4.00 price objective on the stock.

A number of other equities analysts have also weighed in on the company. Cantor Fitzgerald lowered Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the stock from $22.00 to $3.00 in a report on Thursday, September 12th. Leerink Partnrs lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Bank of America downgraded Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Finally, Leerink Partners reiterated a “market perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Trading Down 9.5 %

Fulcrum Therapeutics stock opened at $3.01 on Thursday. The firm has a market cap of $187.51 million, a price-to-earnings ratio of -9.69 and a beta of 2.24. Fulcrum Therapeutics has a 12 month low of $2.87 and a 12 month high of $13.70. The stock has a fifty day simple moving average of $3.75 and a two-hundred day simple moving average of $6.48.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds have recently modified their holdings of the company. Jane Street Group LLC lifted its stake in shares of Fulcrum Therapeutics by 54.3% during the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock valued at $5,051,000 after buying an additional 188,212 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Fulcrum Therapeutics in the second quarter valued at about $3,084,000. Vanguard Group Inc. boosted its stake in shares of Fulcrum Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock worth $23,965,000 after acquiring an additional 18,681 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Fulcrum Therapeutics during the first quarter worth about $308,000. Finally, Dimensional Fund Advisors LP raised its stake in Fulcrum Therapeutics by 13.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock valued at $9,182,000 after purchasing an additional 176,114 shares during the period. 89.83% of the stock is currently owned by institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.